ITM11 Expanded Access Program

Sponsor: ITM Solucin GmbH

Expanded Access
Sponsor score: 0

ClinicalTrials ID:NCT07497984

The ITM11 Expanded Access Program offers ITM-11, an investigational IV drug, to eligible patients before regulatory approval. Eligibility is determined by the treating physician based on medical history and program criteria, ensuring potential benefits outweigh risks. Availability varies by country.

Patient Parameters

Program Overview

This Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´s medical history and the program eligibility criteria, whether the potential benefits outweigh the risks of treatment with an investigational therapy.

Eligibility Criteria

Inclusion Criteria

-

Exclusion Criteria

-

Get This Program In Your Inbox

You can sign up and apply your patients for this program.